Jul 20,2017

Insulet to Assume Distribution and Commercial Support for Its Omnipod® System in Europe

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced plans to assume, on July 1, 2018, the distribution, sales, marketing, training and support activities of Insulet's Omnipod System across Europe following the expiration of the Company's global distribution agreement with Ypsomed AG (Ypsomed) on June 30, 2018.

PRODUCT

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Jul 20,2017

Nemaura Signs Letter of Intent for Licensing Agreement with TPM for GCC Region

Nemaura Medical Inc. (OTCQB: NMRD), a medical technology company focused on the development and commercialization of sugarBEAT®, a wireless disposable adhesive skin-patch for adjunctive use by diabetics as a non-invasive and needle-free continuous glucose monitoring (CGM) system announced today it has signed a non-binding letter of intent with The Principals MENA DMCC (“TPM”) for an exclusive license to market and sell sugarBEAT® in the Gulf Co-operation Council region (“GCC Region”), which consists of Bahrain, Kuwait, Qatar, Saudi Arabia, Oman and United Arab Emirates.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Jul 24,2017

DarioHealth Announces Strategic Partnership with CCS Medical

DarioHealth Corp., a leading global digital health company with mobile health and big data solutions, today announced that it has entered into a strategic agreement with CCS Medical and their LivingConnected clinical program. Through this strategic agreement and proprietary API, DarioHealth is partnering with CCS Medical by providing live data access to CCS Medical for patients that join the LivingConnected clinical program using the DarioHealth native smartphone app. In addition, CCS Medical will take an active role in the DarioHealth Insurance Provider Network, thereby further growing DarioHealth's expansion into the insurance reimbursement option launched earlier this year.

COLLABORATION PARTNERSHIP

#institution

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jul 25,2017

DarioHealth Partners with Byram Healthcare to Further Expand Insurance Health Coverage for U.S. Consumers

DarioHealth Corp. today announced that it is expanding its insurance coverage provider network by entering into a strategic agreement with New York-based Byram Healthcare. Byram is a market-leading distributor of reimbursable medical supplies to home patients and home health agencies in the United States. As reported last month, DarioHealth expanded its 3rd party insurance coverage option for U.S. consumers who want their DarioHealth products reimbursed by insurance. With the addition of Byram Healthcare, DarioHealth expects to cover 30% of consumers in the U.S. diabetes market. In just a few months since launching the insurance health coverage initiative, DarioHealth has received feedback, and covered major insurance plans, such as Aetna, United HealthCare, and various Blue Cross Blue Shield programs.

COLLABORATION PARTNERSHIP

#institution

#bgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jul 26,2017

Nemaura Appoints Dr. Salim Natha to Board of Directors as Independent Director, Chair of Compensation Committee

Nemaura Medical Inc. (OTCQB: NMRD), a medical technology company focused on the development and commercialization of sugarBEAT®, a wireless disposable adhesive skin-patch for adjunctive use by diabetics as a non-invasive and needle-free continuous glucose monitoring (CGM) system announced today that it has appointed Dr. Salim Natha to the company’s Board of Directors. Dr. Natha will serve as an independent director of the company and chair the board’s Compensation Committee.

View Analyst & Ambassador Comments
Go to original news
Jul 27,2017

X.GLU smart glucose meter for kids wins Microsoft's Imagine Cup competition

Microsoft’s annual Imagine Cup, a global competition of high-tech student projects, reached its culmination this week accompanied by the usual pomp at the company’s headquarters in Redmond. The winner of the $100,000 grand prize and 365 days of bragging rights is X.GLU, a Czech team that created a custom smart glucose meter for children with diabetes.

FUNDING GRANT
View Analyst & Ambassador Comments
Go to original news
Jul 27,2017

Tandem Diabetes Care Reports Second Quarter 2017 Financial Results

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today reported its financial results for the quarter ended June 30, 2017. A total of 3,427 pumps were shipped in the second quarter of 2017, compared to 2,816 in the first quarter of 2017, and 4,582 in the second quarter of 2016 when sales and gross margin benefited from a continuation of high customer interest in the t:slim G4™ Insulin Pump, which launched in September of 2015 as the Company's first insulin pump featuring continuous glucose monitoring integration.

View Analyst & Ambassador Comments
Go to original news
Aug 02,2017

Fruit Street Health raises $3 million in doctors-only round

Fruit Street Health, a digital health and telemedicine company currently focused on delivering a digital diabetes prevention program, has raised $3 million in new funding from physician investors. Dr. Jeremy Tucker, a senior emergency medicine physician on the board of directors of Fruit Street, led the round, which brings the company's total funding to $8.4 million.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Aug 03,2017

Dexcom looks ahead to widening CGM market in Q2 call

DexCom hasn’t been shy about its plan for opening up the CGM market by encouraging CGM use in a wider group of people with diabetes — including, eventually, people with Type 2 diabetes. On its second quarter earnings call, the company went deep on that focus on the future. The company’s long-term planning is starting to pay off. DexCom made a net GAAP income of $2.9 million in the quarter, and increased revenue from $137 million in Q2 2016 to $171 million last quarter. The company also raised $400 million at convertible senior notes with favorable financial terms.

View Analyst & Ambassador Comments
Go to original news
Aug 21,2017

In study, Dexcom finds CGMs can benefit Type 2 patients, too

A new study published today in Annals of Internal Medicine and sponsored by Dexcom shows that a continuous glucose monitor could lower the HbA1c scores of people with Type 2 diabetes, and that acceptance of the technology is high among that group as well.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES